4.7 Article

Individualized Gaussian process-based prediction and detection of local and global gray matter abnormalities in elderly subjects

期刊

NEUROIMAGE
卷 97, 期 -, 页码 333-348

出版社

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.neuroimage.2014.04.018

关键词

Brain morphology; Lifespan brain aging; Gaussian processes; Single case analysis; Bayesian inference

资金

  1. PostdocProgram of the German Academic Exchange Service (DAAD)
  2. BMBF [01EV0709]
  3. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  4. National Institute on Aging
  5. National Institute of Biomedical Imaging and Bioengineering
  6. Open Access Series of Imaging Studies (OASIS) [P50 AG05681, P01 AG03991, R01 AG021910, P50 MH071616, U24 RR021382, R01 MH56584]
  7. Medical Research Council [MR/J014257/1]
  8. Wellcome Trust [091593/Z/10/Z]
  9. Abbott
  10. Alzheimer's Association
  11. Alzheimer's Drug Discovery Foundation
  12. Amorfix Life Sciences Ltd.
  13. AstraZeneca
  14. Bayer HealthCare
  15. BioClinica, Inc.
  16. Biogen Idec Inc.
  17. Bristol-Myers Squibb Company
  18. Eisai Inc.
  19. Elan Pharmaceuticals Inc.
  20. Eli Lilly and Company
  21. F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.
  22. GE Healthcare
  23. Innogenetics, N.V.
  24. Janssen Alzheimer Immunotherapy Research AMP
  25. Development, LLC
  26. Johnson AMP
  27. Johnson Pharmaceutical Research AMP
  28. Development LLC.
  29. Medpace, Inc.
  30. Merck Co., Inc.
  31. Meso Scale Diagnostics, LLC.
  32. Novartis Pharmaceuticals Corporation
  33. Pfizer Inc.
  34. Servier
  35. Synarc Inc.
  36. Takeda Pharmaceutical Company
  37. Medical Research Council [MR/J014257/1] Funding Source: researchfish
  38. MRC [MR/J014257/1] Funding Source: UKRI

向作者/读者索取更多资源

Structural imaging based on MRI is an integral component of the clinical assessment of patients with potential dementia. We here propose an individualized Gaussian process-based inference scheme for clinical decision support in healthy and pathological aging elderly subjects using MRI. The approach aims at quantitative and transparent support for clinicians who aim to detect structural abnormalities in patients at risk of Alzheimer's disease or other types of dementia. Firstly, we introduce a generative model incorporating our knowledge about normative decline of local and global gray matter volume across the brain in elderly. By supposing smooth structural trajectories the models account for the general course of age-related structural decline as well as late-life accelerated loss. Considering healthy subjects' demography and global brain parameters as informative about normal brain aging variability affords individualized predictions in single cases. Using Gaussian process models as a normative reference, we predict new subjects' brain scans and quantify the local gray matter abnormalities in terms of Normative Probability Maps (NPM) and global z-scores. By integrating the observed expectation error and the predictive uncertainty, the local maps and global scores exploit the advantages of Bayesian inference for clinical decisions and provide a valuable extension of diagnostic information about pathological aging. We validate the approach in simulated data and real MRI data. We train the GP framework using 1238 healthy subjects with ages 18-94 years, and predict in 415 independent test subjects diagnosed as healthy controls, Mild Cognitive Impairment and Alzheimer's disease. (C) 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据